Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1964 2
1965 1
1966 2
1967 2
1968 2
1969 6
1970 1
1972 4
1973 2
1974 2
1975 4
1976 5
1978 6
1979 4
1980 2
1981 3
1982 2
1984 1
1985 2
1986 3
1988 1
1989 3
1990 3
1991 1
1992 6
1993 3
1994 2
1995 1
1996 3
1997 5
1998 4
1999 5
2000 5
2001 7
2002 8
2003 5
2004 13
2005 9
2006 9
2007 7
2008 14
2009 8
2010 13
2011 10
2012 18
2013 20
2014 26
2015 22
2016 22
2017 20
2018 27
2019 20
2020 14
2021 32
2022 29
2023 32
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

448 results

Results by year

Filters applied: . Clear all
Page 1
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investigators. Scully M, et al. N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9. N Engl J Med. 2019. PMID: 30625070 Free article. Clinical Trial.
BACKGROUND: In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor-cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis, which re …
BACKGROUND: In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand …
Thrombotic thrombocytopenic purpura.
Kremer Hovinga JA, Coppo P, Lämmle B, Moake JL, Miyata T, Vanhoorelbeke K. Kremer Hovinga JA, et al. Nat Rev Dis Primers. 2017 Apr 6;3:17020. doi: 10.1038/nrdp.2017.20. Nat Rev Dis Primers. 2017. PMID: 28382967 Review.
Thrombotic thrombocytopenic purpura (TTP; also known as Moschcowitz disease) is characterized by the concomitant occurrence of often severe thrombocytopenia, microangiopathic haemolytic anaemia and a variable degree of ischaemic organ damage, particularly aff …
Thrombotic thrombocytopenic purpura (TTP; also known as Moschcowitz disease) is characterized by the concomitant occurr …
Cardiac implications of thrombotic thrombocytopenic purpura.
Wiernek SL, Jiang B, Gustafson GM, Dai X. Wiernek SL, et al. World J Cardiol. 2018 Dec 26;10(12):254-266. doi: 10.4330/wjc.v10.i12.254. World J Cardiol. 2018. PMID: 30622684 Free PMC article. Review.
Thrombotic thrombocytopenic purpura (TTP) is a multisystem disorder that essentially can affect any organ in the human body. ...Clinical manifestations of cardiac involvement in TTP vary dramatically, from asymptomatic elevation of cardiac bioma …
Thrombotic thrombocytopenic purpura (TTP) is a multisystem disorder that essentially can affect any organ in the human …
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D; TITAN Investigators. Peyvandi F, et al. N Engl J Med. 2016 Feb 11;374(6):511-22. doi: 10.1056/NEJMoa1505533. N Engl J Med. 2016. PMID: 26863353 Free article. Clinical Trial.
BACKGROUND: Acquired thrombotic thrombocytopenic purpura (TTP) is caused by aggregation of platelets on ultralarge von Willebrand factor multimers. ...
BACKGROUND: Acquired thrombotic thrombocytopenic purpura (TTP) is caused by aggregation of platelets on ultralarge von …
Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.
Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, Lämmle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H; International Working Group for Thrombotic Thrombocytopenic Purpura. Scully M, et al. J Thromb Haemost. 2017 Feb;15(2):312-322. doi: 10.1111/jth.13571. Epub 2017 Jan 30. J Thromb Haemost. 2017. PMID: 27868334 Free article.
Essentials An international collaboration provides a consensus for clinical definitions. This concerns thrombotic microangiopathies and thrombotic thrombocytopenic purpura (TTP). ...Requirements for ADAMTS-13 are given. SUMMARY: Background Thromboti …
Essentials An international collaboration provides a consensus for clinical definitions. This concerns thrombotic microangiopathies a …
Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review.
Hawkins BM, Abu-Fadel M, Vesely SK, George JN. Hawkins BM, et al. Transfusion. 2008 Feb;48(2):382-92. doi: 10.1111/j.1537-2995.2007.01534.x. Epub 2007 Nov 19. Transfusion. 2008. PMID: 18028268 Review.
BACKGROUND: Autopsy studies consistently demonstrate cardiac involvement in thrombotic thrombocytopenic purpura (TTP), but clinical evidence for cardiac abnormalities is rarely reported. ...Prospective studies are needed to determine if cardi …
BACKGROUND: Autopsy studies consistently demonstrate cardiac involvement in thrombotic thrombocytopenic purpura …
The Specificities of Thrombotic Thrombocytopenic Purpura at Extreme Ages: A Narrative Review.
Joseph A, Joly BS, Picod A, Veyradier A, Coppo P. Joseph A, et al. J Clin Med. 2023 Apr 23;12(9):3068. doi: 10.3390/jcm12093068. J Clin Med. 2023. PMID: 37176509 Free PMC article. Review.
Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy (TMA) related to a severe ADAMTS13 deficiency, the specific von Willebrand factor (VWF)-cleaving protease. ...In contrast, older iTTP patients have an a …
Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy (TMA) relate …
Extracorporeal membrane oxygenation-hemostatic complications.
Murphy DA, Hockings LE, Andrews RK, Aubron C, Gardiner EE, Pellegrino VA, Davis AK. Murphy DA, et al. Transfus Med Rev. 2015 Apr;29(2):90-101. doi: 10.1016/j.tmrv.2014.12.001. Epub 2014 Dec 18. Transfus Med Rev. 2015. PMID: 25595476 Review.
Patients requiring ECMO are a heterogenous group of critically ill patients with cardiac and respiratory failure. Bleeding and thrombotic complications remain a leading cause of morbidity and mortality in patients on ECMO. In this review, we describe the mechanisms …
Patients requiring ECMO are a heterogenous group of critically ill patients with cardiac and respiratory failure. Bleeding and thr …
Etiology and Outcomes of Thrombotic Microangiopathies.
Bayer G, von Tokarski F, Thoreau B, Bauvois A, Barbet C, Cloarec S, Mérieau E, Lachot S, Garot D, Bernard L, Gyan E, Perrotin F, Pouplard C, Maillot F, Gatault P, Sautenet B, Rusch E, Buchler M, Vigneau C, Fakhouri F, Halimi JM. Bayer G, et al. Clin J Am Soc Nephrol. 2019 Apr 5;14(4):557-566. doi: 10.2215/CJN.11470918. Epub 2019 Mar 12. Clin J Am Soc Nephrol. 2019. PMID: 30862697 Free PMC article.
Secondary thrombotic microangiopathies are less characterized than primary thrombotic microangiopathies (thrombotic thrombocytopenic purpura and atypical hemolytic and uremic syndrome). ...RESULTS: We identified primary thrombotic microan …
Secondary thrombotic microangiopathies are less characterized than primary thrombotic microangiopathies (thrombotic …
448 results